Erschienen in:
21.12.2016 | Short Communication
Assessment of urinary microparticles in normotensive patients with type 1 diabetes
verfasst von:
Yuliya Lytvyn, Fengxia Xiao, Christopher R. J. Kennedy, Bruce A. Perkins, Heather N. Reich, James W. Scholey, David Z. Cherney, Dylan Burger
Erschienen in:
Diabetologia
|
Ausgabe 3/2017
Einloggen, um Zugang zu erhalten
Abstract
Aims/hypothesis
Assessment of urinary extracellular vesicles including exosomes and microparticles (MPs) is an emerging approach for non-invasive detection of renal injury. We have previously reported that podocyte-derived MPs are increased in diabetic mice in advance of albuminuria. Here, we hypothesised that type 1 diabetes and acute hyperglycaemia would increase urinary podocyte MP levels in uncomplicated diabetes.
Methods
In this post hoc exploratory analysis, we examined archived urine samples from normoalbuminuric patients with uncomplicated type 1 diabetes studied under clamped euglycaemia and hyperglycaemia and compared with healthy controls. Urinary vesicles were assessed by electron microscopy and nanoparticle tracking while podocyte MPs were assessed by flow cytometry.
Results
Neither vesicle size nor total number were significantly altered in type 1 diabetes or acute hyperglycaemia. By contrast, urinary podocyte MP levels were higher in type 1 diabetes (0.47 [0.00–3.42] MPs/μmol creatinine [Cr]) compared with healthy controls (0.00 [0.00–0.00] MPs/μmol Cr, p < 0.05) and increased under hyperglycaemic clamp (0.36 [0.00–4.15] MPs/μmol Cr during euglycaemia vs 2.70 [0.00–15.91] MPs/μmol Cr during hyperglycaemia, p < 0.05). Levels of urinary albumin to creatinine ratio and nephrin (surrogates of podocyte injury) were unchanged by type 1 diabetes or acute hyperglycaemia.
Conclusion/interpretation
Taken together, our data show that urinary podocyte MP levels are higher in patients with type 1 diabetes in advance of changes in other biomarkers (albuminuria, nephrin). Examination of podocyte MPs may serve as an early biomarker of glomerular injury in uncomplicated type 1 diabetes.